EP0995757A2 — Bivalent inhibitors of the proteasome
Assigned to Max Planck Gesellschaft zur Foerderung der Wissenschaften eV · Expires 2000-04-26 · 26y expired
What this patent protects
The invention comprises a bivalent proteasome inhibitor compound comprising two head groups and a spacer linking the two head groups and, wherein the two head groups can be the same or different and are each capable of inhibiting one or more active sites of the proteasome and whe…
USPTO Abstract
The invention comprises a bivalent proteasome inhibitor compound comprising two head groups and a spacer linking the two head groups and, wherein the two head groups can be the same or different and are each capable of inhibiting one or more active sites of the proteasome and wherein the spacer comprises a flexible, substantially linear organic compound with a length of 25 ANGSTROM to 100 ANGSTROM .
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.